Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy
← catalyst calendarNCT06618547 · readout ≤ 103 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2025 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myopia
Intervention
- Device: TENEO 317 Model 2 excimer laser
Primary outcomes
what the primary-completion date above is the date OFMaintenance of BCDVA -
measured through study completion, an average of 1 year
Maintenance of BCDVA -
measured through study completion, an average of 1 year
Induced manifest refractive astigmatism
measured through study completion, an average of 1 year
Induced manifest refractive astigmatism
measured through study completion, an average of 1 year
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed